Novel mutations in tyrosine kinase domain of epidermal growth factor receptor in prostate cancer.

被引：0
|
作者：
Douglas, D.
Zhong, H.
Ro, J.
Oddoux, C.
Pincus, M.
Satagopan, J.
Gerald, W.
Schei, H.
Lee, P.
Osman, I.
机构：
[1] NYU, Sch Med, New York, NY USA
[2] Asan Med Ctr, Seoul, South Korea
[3] New York Harbor VA Med Ctr, Brooklyn, NY USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：244S / 244S
页数：1
相关论文
共 50 条
  • [21] Development of positron labeled epidermal growth factor receptor tyrosine kinase inhibitors: Pet probes for breast cancer.
    VanBrocklin, HF
    Gibbs, AR
    Hanrahan, SM
    Hom, DL
    Lim, JK
    Riese, DJ
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U13 - U14
  • [22] EKB-569: a new irreversible inhibitor of epidermal growth factor receptor tyrosine kinase for the treatment of cancer.
    Greenberger, LM
    Discafani, C
    Wang, YF
    Tsou, HR
    Overbeek, EG
    Nilakantan, R
    Frost, P
    Wissner, A
    CLINICAL CANCER RESEARCH, 2000, 6 : 4544S - 4544S
  • [23] ACTIVATION OF THE PURIFIED PROTEIN TYROSINE KINASE DOMAIN OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR
    WEDEGAERTNER, PB
    GILL, GN
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1989, 264 (19) : 11346 - 11353
  • [24] MODERN VECTOR IN TREATMENT OF PATIENTS WITH LUNG CANCER: TYROSINE KINASE INHIBITORS IN EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS
    Smorodska, O. M.
    Moskalenko, Yu, V
    Vynnychenko, I. O.
    Vynnychenko, O., I
    Kostuchenko, V. V.
    MEDICNI PERSPEKTIVI, 2021, 26 (02): : 4 - 11
  • [25] Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations
    Moran, Teresa
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) : 3330 - 3336
  • [26] Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients
    Murray, S
    Timotheadou, E
    Linardou, H
    Vrettou, A
    Kostopoulos, I
    Skrickova, J
    Papakostantinou, C
    Christodoulou, C
    Pectasides, D
    Samantas, E
    Papakostas, P
    Skarlos, DV
    Kosmidis, P
    Fountzilas, G
    LUNG CANCER, 2006, 52 (02) : 225 - 233
  • [27] Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives
    Kelloff, GJ
    Fay, JR
    Steele, VE
    Lubet, RA
    Boone, CW
    Crowell, JA
    Sigman, CC
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1996, 5 (08) : 657 - 666
  • [28] Strategies for Molecular Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase in Cancer
    Mishani, Eyal
    Hagooly, Aviv
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (08) : 1199 - 1202
  • [29] Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Tsai, CM
    Chiu, CH
    Chou, TY
    Li, LH
    Hsiao, CY
    Chen, M
    Perng, RP
    Tsai, SF
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 641S - 641S
  • [30] Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas
    Dahse, R.
    Driemel, O.
    Schwarz, S.
    Dahse, J.
    Kromeyer-Hauschild, K.
    Berndt, A.
    Kosmehl, H.
    BRITISH JOURNAL OF CANCER, 2009, 100 (04) : 623 - 625
12345